CareDx Inc
CDNA19.470USD
+1.120+6.10%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
1.00BMarket Cap
14.43P/E TTM
More Details of CareDx Inc Company
CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the provider of genomics-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Its lab product portfolio includes QTYPE, Olerup SSP and SBT, AlloSeq Tx, AlloSeq HCT, and AlloSeq cfDNA. It also offers a diverse portfolio of digital solutions to transplant centers.
CareDx Inc Info
Ticker SymbolCDNA
Company nameCareDx Inc
IPO dateJul 17, 2014
CEOHanna (John W)
Number of employees644
Security typeOrdinary Share
Fiscal year-endJul 17
Address8000 Marina Blvd
CityBRISBANE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94005
Phone14152872300
Websitehttps://www.caredx.com/
Ticker SymbolCDNA
IPO dateJul 17, 2014
CEOHanna (John W)
Company Executives of CareDx Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Peter Maag, Ph.D.
Dr. Peter Maag, Ph.D.
Independent Director
Independent Director
298.28K
-10000.00%
Mr. Michael D. Goldberg
Mr. Michael D. Goldberg
Independent Chairman of the Board
Independent Chairman of the Board
146.89K
+1492.00%
Dr. Frederick E. (Fred) Cohen, M.D.
Dr. Frederick E. (Fred) Cohen, M.D.
Independent Director
Independent Director
144.69K
+12103.00%
Ms. Jessica Meng
Ms. Jessica Meng
Chief Commercial Officer
Chief Commercial Officer
109.63K
-4703.00%
Mr. William A. (Bill) Hagstrom
Mr. William A. (Bill) Hagstrom
Independent Director
Independent Director
43.41K
--
Mr. Nathan Smith
Mr. Nathan Smith
Chief Financial Officer
Chief Financial Officer
42.00K
+42000.00%
Ms. Christine M. Cournoyer
Ms. Christine M. Cournoyer
Independent Director
Independent Director
38.58K
+12103.00%
Mr. Suresh Gunasekaran
Mr. Suresh Gunasekaran
Director
Director
27.45K
+27453.00%
Mr. Jeffrey Adam Novack
Mr. Jeffrey Adam Novack
General Counsel, Secretary
General Counsel, Secretary
10.20K
-7293.00%
Mr. Keith Kennedy
Mr. Keith Kennedy
Chief Operating Officer
Chief Operating Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Peter Maag, Ph.D.
Dr. Peter Maag, Ph.D.
Independent Director
Independent Director
298.28K
-10000.00%
Mr. Michael D. Goldberg
Mr. Michael D. Goldberg
Independent Chairman of the Board
Independent Chairman of the Board
146.89K
+1492.00%
Dr. Frederick E. (Fred) Cohen, M.D.
Dr. Frederick E. (Fred) Cohen, M.D.
Independent Director
Independent Director
144.69K
+12103.00%
Ms. Jessica Meng
Ms. Jessica Meng
Chief Commercial Officer
Chief Commercial Officer
109.63K
-4703.00%
Mr. William A. (Bill) Hagstrom
Mr. William A. (Bill) Hagstrom
Independent Director
Independent Director
43.41K
--
Mr. Nathan Smith
Mr. Nathan Smith
Chief Financial Officer
Chief Financial Officer
42.00K
+42000.00%
Revenue Breakdown
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Testing Service revenue
72.17M
0.00%
Digital and other revenue
15.41M
0.00%
Product revenue
12.48M
0.00%
By RegionUSD
Name
Revenue
Proportion
United States
95.06M
0.00%
Rest of the world
5.00M
0.00%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Testing Service revenue
72.17M
0.00%
Digital and other revenue
15.41M
0.00%
Product revenue
12.48M
0.00%
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
8.01%
The Vanguard Group, Inc.
6.64%
Baron Capital Management, Inc.
6.13%
State Street Investment Management (US)
4.99%
Ophir Asset Management Pty Ltd
4.27%
Other
69.95%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
8.01%
The Vanguard Group, Inc.
6.64%
Baron Capital Management, Inc.
6.13%
State Street Investment Management (US)
4.99%
Ophir Asset Management Pty Ltd
4.27%
Other
69.95%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
41.70%
Investment Advisor
35.08%
Hedge Fund
21.15%
Individual Investor
4.50%
Research Firm
3.27%
Pension Fund
0.56%
Bank and Trust
0.41%
Insurance Company
0.03%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
443
52.64M
115.22%
+43.46K
2025Q3
457
52.61M
115.96%
-1.80M
2025Q2
454
53.72M
112.39%
-1.85M
2025Q1
443
55.89M
106.19%
-3.01M
2024Q4
439
52.97M
108.30%
+1.05M
2024Q3
434
51.58M
120.50%
-825.62K
2024Q2
407
52.51M
127.45%
-1.22M
2024Q1
435
53.86M
132.45%
-14.73M
2023Q4
448
52.78M
128.80%
-2.04M
2023Q3
476
54.42M
142.26%
-1.69M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
4.12M
8.01%
+53.87K
+1.33%
Sep 30, 2025
The Vanguard Group, Inc.
3.74M
7.27%
-1.16M
-23.69%
Sep 30, 2025
Baron Capital Management, Inc.
3.16M
6.13%
+719.52K
+29.54%
Sep 30, 2025
State Street Investment Management (US)
2.57M
4.99%
+386.30K
+17.72%
Sep 30, 2025
Ophir Asset Management Pty Ltd
2.20M
4.27%
+304.95K
+16.11%
Sep 30, 2025
Deerfield Management Company, L.P.
2.19M
4.26%
+2.19M
--
Sep 30, 2025
Braidwell LP
2.18M
4.24%
+2.18M
--
Sep 30, 2025
ARK Investment Management LLC
2.17M
4.22%
+70.47K
+3.36%
Sep 30, 2025
Gagnon Securities LLC
1.73M
3.36%
-404.70K
-18.96%
Sep 30, 2025
Amova Asset Management Co., Ltd.
1.74M
3.38%
+503.14K
+40.68%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ARK Genomic Revolution ETF
2.89%
ROBO Global Healthcare Technology & Innovation ETF
1.93%
Global X Genomics & Biotechnology ETF
0.87%
Franklin Genomic Advancements ETF
0.72%
State Street SPDR S&P Biotech ETF
0.34%
Direxion Daily S&P Biotech Bull 3X Shares
0.21%
iShares Micro-Cap ETF
0.16%
Fidelity Enhanced Small Cap ETF
0.11%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.11%
Principal U.S. Small-Cap ETF
0.1%
View more
ARK Genomic Revolution ETF
Proportion2.89%
ROBO Global Healthcare Technology & Innovation ETF
Proportion1.93%
Global X Genomics & Biotechnology ETF
Proportion0.87%
Franklin Genomic Advancements ETF
Proportion0.72%
State Street SPDR S&P Biotech ETF
Proportion0.34%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.21%
iShares Micro-Cap ETF
Proportion0.16%
Fidelity Enhanced Small Cap ETF
Proportion0.11%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.11%
Principal U.S. Small-Cap ETF
Proportion0.1%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
